Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for Treatment of Refractory Advanced Colorectal Cancer
07-Apr-2010 -
Æterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt ...
colorectal cancer
food
metastatic colorectal cancer